146 related articles for article (PubMed ID: 29641422)
21. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
Hayes DF; Yamauchi H; Broadwater G; Cirrincione CT; Rodrigue SP; Berry DA; Younger J; Panasci LL; Millard F; Duggan DB; Norton L; Henderson IC;
Clin Cancer Res; 2001 Sep; 7(9):2703-11. PubMed ID: 11555582
[TBL] [Abstract][Full Text] [Related]
22. Prognostic and predictive impact of the HER-2/ neu extracellular domain (ECD) in the serum of patients treated with chemotherapy for metastatic breast cancer.
Müller V; Witzel I; Lück HJ; Köhler G; von Minckwitz G; Möbus V; Sattler D; Wilczak W; Löning T; Jänicke F; Pantel K; Thomssen C
Breast Cancer Res Treat; 2004 Jul; 86(1):9-18. PubMed ID: 15218357
[TBL] [Abstract][Full Text] [Related]
23. [Serum osteocalcin and bone alkaline phosphatase in healthy children in relation to age and gender].
Ambroszkiewicz J; Gajewska J; Laskowska-Klita T
Med Wieku Rozwoj; 2002; 6(3):257-65. PubMed ID: 12637780
[TBL] [Abstract][Full Text] [Related]
24. Three hematological indexes that may serve as prognostic indicators in patients with primary, high-grade, appendicular osteosarcoma.
Hu K; Wang Z; Lin P; Wen Z; Ren H; Sun L; Li H; Li B; Wang S; Zhou X; Tengwang S; Xu L; Ye Z
Oncotarget; 2017 Jun; 8(26):43130-43139. PubMed ID: 28562345
[TBL] [Abstract][Full Text] [Related]
25. Plasma proteome predicts chemotherapy response in osteosarcoma patients.
Li Y; Dang TA; Shen J; Hicks J; Chintagumpala M; Lau CC; Man TK
Oncol Rep; 2011 Feb; 25(2):303-14. PubMed ID: 21165584
[TBL] [Abstract][Full Text] [Related]
26. The effect of growth hormone treatment on serum bone alkaline phosphatase in growth hormone deficient children.
Korpal-Szczyrska M; Balcerska A
Pediatr Endocrinol Diabetes Metab; 2008; 14(4):211-4. PubMed ID: 19239787
[TBL] [Abstract][Full Text] [Related]
27. Usefulness of bone markers for detection of bone metastases in lung cancer patients.
Alataş F; Alataş O; Metintaş M; Colak O; Erginel S; Harmanci E
Clin Biochem; 2002 Jun; 35(4):293-6. PubMed ID: 12135691
[TBL] [Abstract][Full Text] [Related]
28. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
29. Correlation between prognostic factors and blood variables in osteosarcoma.
Broström LA; Ingimarsson S; Strander H; Eklund G
Acta Med Scand; 1980; 207(5):429-31. PubMed ID: 6930152
[TBL] [Abstract][Full Text] [Related]
30. Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma.
Kim SH; Shin KH; Moon SH; Jang J; Kim HS; Suh JS; Yang WI
Cancer Med; 2017 Jun; 6(6):1311-1322. PubMed ID: 28493412
[TBL] [Abstract][Full Text] [Related]
31. Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy.
Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
Hum Pathol; 1998 Oct; 29(10):1050-5. PubMed ID: 9781640
[TBL] [Abstract][Full Text] [Related]
32. Proteins expressed in osteosarcoma and serum levels as prognostic factors.
Trieb K; Kotz R
Int J Biochem Cell Biol; 2001 Jan; 33(1):11-7. PubMed ID: 11167128
[TBL] [Abstract][Full Text] [Related]
33. Randomized, crossover comparison study of the short-term effect of oral testosterone undecanoate and intramuscular testosterone depot on linear growth and serum bone alkaline phosphatase.
Ahmed SF; Tucker P; Mayo A; Wallace AM; Hughes IA
J Pediatr Endocrinol Metab; 2004 Jul; 17(7):941-50. PubMed ID: 15301041
[TBL] [Abstract][Full Text] [Related]
34. [Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management].
Mathelin C; Croce S; Rault S; Gharbi M; Eichler F; Gairard B; Coumaros G; Koehl C
Presse Med; 2011 Feb; 40(2):126-37. PubMed ID: 21074348
[TBL] [Abstract][Full Text] [Related]
35. Activity or mass concentration of bone-specific alkaline phosphatase as a marker of bone formation.
Avbersek-Luznik I; Gmeiner Stopar T; Marc J
Clin Chem Lab Med; 2007; 45(8):1014-8. PubMed ID: 17579570
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of serum alkaline phosphatase in osteosarcoma of the extremity treated with neoadjuvant chemotherapy: recent experience at Rizzoli Institute.
Bacci G; Longhi A; Ferrari S; Lari S; Manfrini M; Donati D; Forni C; Versari M
Oncol Rep; 2002; 9(1):171-5. PubMed ID: 11748477
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of selected cytokines in children and adolescents with osteosarcoma at diagnosis - preliminary report].
Markiewicz K; Zeman K; Kozar A; Gołebiowska-Wawrzyniak M
Med Wieku Rozwoj; 2011; 15(1):25-31. PubMed ID: 21786509
[TBL] [Abstract][Full Text] [Related]
38. Role of routine blood tests for predicting clinical outcomes in osteosarcoma patients.
Jettoo P; Tan G; Gerrand CH; Rankin KS
J Orthop Surg (Hong Kong); 2019; 27(2):2309499019838293. PubMed ID: 30909848
[TBL] [Abstract][Full Text] [Related]
39. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases.
Berruti A; Dogliotti L; Gorzegno G; Torta M; Tampellini M; Tucci M; Cerutti S; Frezet MM; Stivanello M; Sacchetto G; Angeli A
Clin Chem; 1999 Aug; 45(8 Pt 1):1240-7. PubMed ID: 10430790
[TBL] [Abstract][Full Text] [Related]
40. Different distributions of human bone alkaline phosphatase isoforms in serum and bone tissue extracts.
Magnusson P; Sharp CA; Farley JR
Clin Chim Acta; 2002 Nov; 325(1-2):59-70. PubMed ID: 12367767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
